Liquidity & Technical

Liquidity & Technical

Gogoro is institutionally untradeable in size under normal participation limits: 20-day average daily turnover sits at roughly $47k, and a position as small as 0.5% of the $59M market cap takes about 32 trading days to clear at a disciplined 20%-of-ADV exit. The tape is constructive in the very near term — price has bounced 46% off the December 2025 low of $2.74 and just retook the 50-day average — but it is still living below a falling 200-day, momentum is neutral rather than bullish, and the only structural cross signal of the last three years is the death cross fired in April 2022 that has never been repaired.

1. Portfolio implementation verdict

2. Price snapshot

The all-time high of $295 (April 2022, day of SPAC debut) is a separate company-history datapoint, not a level to trade against — current price is 98.6% below it. What matters now is that the stock sits in the lower quartile of its 52-week range with realized vol cooling into the calmest band of its five-year distribution.

3. Five-year price action — monthly closes, 50d and 200d averages

Price is below the 200-day average ($4.00 close vs $4.29 SMA200, −6.7%). The picture is a five-year secular downtrend interrupted by short-cycle relief rallies. A death cross fired on 2022-04-29 — six trading days after the SPAC debut — and no golden cross has appeared in the four years since. The current bounce off $2.74 has carried price back above the 50-day but has not yet challenged the 200-day from below.

4. Relative strength

No broad-market or sector benchmark series was captured in this run — Taiwan-domiciled foreign issuers listed on NASDAQ are not cleanly mapped to SPY or to a US sector SPDR for this name, and no peer basket was assembled. Absolute returns alone tell the story: −98% from the SPAC debut, −94% over three years, −23% over twelve months. The stock has materially underperformed every benchmark a reader can think of; the question is direction from here, not where it has been.

5. Momentum — RSI(14) and MACD histogram, last 18 months

RSI(14) closed Friday at 49.8 — dead-center neutral, having recovered from oversold readings below 25 in mid-October 2025. The MACD histogram has been flipping back and forth between marginally positive and marginally negative since March; the latest read of −0.016 is essentially zero and signals momentum exhaustion at this level, not directional conviction. Near-term, this is a wait-and-see tape, not a buy or short signal.

6. Volume, volatility, and sponsorship

The volume profile through 2025 is the most useful data point on this whole page: the 50-day average exploded from ~20k shares per day in August 2025 to over 220k by mid-October on a brief reflation rally that took price to $11+, then evaporated to roughly 9k per day by May 2026 — a 95% collapse in turnover in seven months. That is not the footprint of patient sponsorship; that is a single retail-driven liquidity event that has now drained.

Five-year percentile bands (p20 / p50 / p80) sit at 33.6% / 60.7% / 87.9%. The current 38.6% reading sits just above the calm band — historically low for this name. Combined with the volume collapse, the message is consistent: the market is no longer pricing this stock as a story stock. That is supportive for tight execution if a fund were ever to buy here, but reinforces the read that sponsorship has left.

7. Institutional liquidity panel

A. ADV and turnover

Twelve-month turnover of roughly the float once over (100%) is the only normal-looking metric here, and it is heavily concentrated in the September-October 2025 retail event; ex-that-event the run-rate is materially lower.

B. Fund-capacity table

A fund with even modest AUM cannot put on a normal-sized position here. At a disciplined 20%-of-ADV cap over five trading days, a 5% portfolio weight maxes out at about $922k of fund AUM, and a 2% weight maxes at roughly $2.3M. This is a name for high-net-worth specialist accounts, family offices comfortable holding the position through a multi-week build, or merger-arbitrage-style block negotiations.

C. Liquidation runway

A $295k position (0.5% of issuer market cap) needs about six weeks to unwind cleanly at 20% ADV, three months at 10% ADV. Any negative event during that window is unhedgeable in size, and there is no derivatives market to lay off the exposure.

D. Price-range proxy

Median 60-day daily range of 2.04% sits right at the threshold the prompt flags as "elevated impact cost for large orders," and that is for retail-sized clips — institutional clips in this volume profile would widen spread further. Combined with zero-volume-day risk (none in the last 60 days, but the run-rate is thin enough that one bad session could leave a fill incomplete), the friction cost of execution materially impairs any total-return calculation.

Bottom line on liquidity: the largest position that clears at 20% ADV within five trading days rounds to zero percent of market cap, and even the more conservative 10%-ADV book covers only a single-millimeter sliver. Nothing larger than a sub-1% issuer position is cleanly tradeable on a meaningful horizon.

8. Technical scorecard and stance

Stance — neutral with a bearish bias, 3-to-6 month horizon. The tape has stabilized above the 50-day after a $2.74 December low, and momentum has clawed back to neutral, but price still trades 6.7% below a falling 200-day and the only structural cross of the last four years was a death cross that was never repaired by a golden cross. The volume collapse since October says no fresh institutional sponsorship has shown up. The view flips bullish on a daily close above $4.30 (reclaim of the 200-day, which would also coincide with a possible 50/200 golden cross attempt) confirmed by an RSI break above 60; the view flips decisively bearish on a daily close below $2.74 (the December 2025 52-week low), which would open downside toward sub-$2 with no obvious technical support.

Liquidity is the constraint. Even if the technical setup were unambiguous, the correct action for any institutional book is avoid / specialist-only — the name does not support a 5%-position build for any fund larger than roughly $1M of AUM at standard participation limits, and patient block execution would be the only viable path for anything larger. This page should be read as a tape monitor, not an actionable buy/sell signal.